A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab

Active, not recruitingOBSERVATIONAL
Enrollment

303

Participants

Timeline

Start Date

November 28, 2023

Primary Completion Date

May 10, 2028

Study Completion Date

May 10, 2028

Conditions
Atopic Dermatitis
Interventions
DRUG

Dupilumab

Dupilumab cohort

Trial Locations (42)

6300

Investigational Site Number: 2500020, Nice

13008

Investigational Site Number: 2500029, Marseille

14033

Investigational Site Number: 2500043, Caen

21231

Investigational Site Number: 2500005, Dijon

24019

Investigational Site Number: 2500009, Périgueux

25000

Investigational Site Number: 2500001, Besançon

26000

Investigational Site Number: 2500010, Valence

26102

Investigational Site Number: 2500014, Romans-sur-Isère

31059

Investigational Site Number: 2500012, Toulouse

34090

Investigational Site Number: 2500028, Montpellier

38700

Investigational Site Number: 2500045, La Tronche

44093

Investigational Site Number: 2500024, Nantes

44606

Investigational Site Number: 2500026, Saint-Nazaire

49000

Investigational Site Number: 2500037, Angers

54500

Investigational Site Number: 2500031, Vandœuvre-lès-Nancy

56100

Investigational Site Number: 2500036, Lorient

57530

Investigational Site Number: 2500011, Ars-Laquenexy

59037

Investigational Site Number: 2500032, Lille

59280

Investigational Site Number: 2500044, Armentières

62000

Investigational Site Number: 2500018, Arras

63113

Investigational Site Number: 2500006, Clermont-Ferrand

64000

Investigational Site Number: 2500016, Pau

69500

Investigational Site Number: 2500003, Bron

72037

Investigational Site Number: 2500040, Le Mans

73000

Investigational Site Number: 2500050, Chambéry

74370

Investigational Site Number: 2500004, Epagny Metz Tessy

76031

Investigational Site Number: 2500008, Rouen

76083

Investigational Site Number: 2500019, Le Havre

78100

Investigational Site Number: 2500015, Saint-Germain-en-Laye

80054

Investigational Site Number: 2500041, Amiens

84000

Investigational Site Number: 2500023, Avignon

85100

Investigational Site Number: 2500038, Les Sables-d'Olonne

86000

Investigational Site Number: 2500042, Poitiers

87000

Investigational Site Number: 2500002, Limoges

92300

Investigational Site Number: 2500048, Levallois-Perret

94163

Investigational Site Number: 2500027, Saint-Mandé

95107

Investigational Site Number: 2500021, Argenteuil

95300

Investigational Site Number: 2500022, Pontoise

97261

Investigational Site Number: 2500039, Fort-de-France

97410

Investigational Site Number: 2500035, Saint-Pierre

97448

Investigational Site Number: 2500013, Saint-Pierre

06000

Investigational Site Number: 2500025, Nice

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY

NCT06169527 - A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab | Biotech Hunter | Biotech Hunter